Pegaptanib

Drug Profile

Pegaptanib

Alternative Names: anti-VEGF aptamer; BLO 021; EYE-001; Macugen; NX-1838; Pegaptanib octasodium; Pegaptanib sodium

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Developer Eyetech Inc.; Gilead Sciences; Pfizer; Valeant Pharmaceuticals International
  • Class Eye disorder therapies; Nucleotide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration
  • No development reported Diabetic macular oedema; Diabetic retinopathy
  • Discontinued Choroidal neovascularisation; Retinal vascular occlusion

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 15 May 2014 No development reported - Phase-III for Diabetic retinopathy in USA (Intravitreous)
  • 04 Mar 2013 Discontinued - Phase-II for Retinal vascular occlusion in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top